The market for anti-cancer drugs will usher in a high growth

By 2012, total sales of the global cancer drug market will reach $ 80 billion. Newly industrialized countries such as China, India, Brazil and Russia will become the high incidence countries of lung cancer. Smokers in these countries are about 60% of total number of smokers, while smoking is recognized as a reason of induced lung cancer by the docetaxel medical professions.

The number of patients is increasing as levels of medical diagnosis and high-end diagnostic imaging equipment improves rapidly. The number of breast cancer, lung cancer, gastric cancer and other common tumor diseases increase. According to WHO statistics, in 2007, the world's newly diagnosed cancer patients as many as 12 million over the past few years, the world die each year from cancer patients up to 700 million. This figure is very close to the number of people died of acute cardiovascular disease. In addition to the incidence of cancer in the developing and newly industrialized countries increased incidence of cancer in the US-led Western developed countries is equally high.

Statin lipid-lowering drugs throughout the 1990s has been ranked first in the international pharmaceutical raw materials market. In 2005, the total sales are $ 29.5 billion. But it has long been anti-cancer drugs in general beyond the specific varieties. Although sales of statins is still rising, but they are compared with the sales of anti-cancer drugs in recent years is not worth mentioning. Statins to step aside the fact that the anti-cancer drugs will soon become a major drug major categories of varieties dominate the world pharmaceutical market.

U.S. men the highest incidence of neoplastic diseases of prostate cancer a few years ago, and the current lack of effective drugs for the treatment of prostate cancer, so the prostate cancer vaccine in the United States is developing several. To date, bio-engineering vaccine being developed in cancer prevention at least as much as 20 to 30 kinds. Once they put on the market, will greatly enhance the sales of the global cancer drug market.

Insiders predicted that the protein / peptide bio-engineering anti-cancer drugs will become mainstream products in the international anti-cancer drugs on the market in the next few years. This is because compared with the traditional synthetic anti-cancer drugs, protein / peptide anti-cancer drugs on the body less toxic side effects, better patient compliance.

In addition to protein / peptide bio-engineering anti-cancer drugs, plant anti-cancer drugs will become the leading products of the other major categories of international anti-cancer drugs on the market. Most telling is that the paclitaxel injection development listed so far, have been sold in the international pharmaceutical market is evidenced by (cumulative sales of more than 20 billion U.S. dollars). In addition to paclitaxel, the international pharmaceutical market, there are a variety of plant sources of the best-selling anti-cancer drug formulations, such as camptothecin series (topological topotecan, irinotecan etc.), classic old drug spent alkaline series, Ito parked glycosides from the Chinese herbal thunder, oridonin and other factors. It can be believed that, with the continuous increase of pharmaceutical development, the market will have more efficacy and toxicity of plant anticancer drug in the future come out.

China is a big herbal country and has thousands of year’s history in use of Chinese herbs. So the Chinese medicine researchers should make great efforts to filter out efficient anticancer drug from the domestic herbal and adds stamina for upcoming oncology drug market boom.Source:http://www.cospcn.com